Study drug for difficult myeloma after prior treatments
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an anti-CD38 antibody drug that is “linked” to a cancer-killing payload (an antibody-drug conjugate) in people with multiple myeloma that has returned or did not respond to standard treatments. It is mainly looking at safety first, and also whether it can reduce myeloma in heavily pre-treated patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have multiple myeloma that returned or did not respond after your most recent anti-myeloma treatment
- You have already tried at least three prior medicines, including proteasome inhibitor, immunomodulatory drug, and an anti-CD38 antibody
- Your disease has measurable signs (specific lab or urine measures must be above set limits)
- Your daily functioning is fairly good (ECOG 0–2)
- You can follow all study visits and procedures, and you use very effective birth control if you can become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
This study tests a new drug called IBI3003 in people whose multiple myeloma (a blood cancer) has come back or stopped responding to previous treatments. The goal is to see if this drug can shrink the cancer and help patients live longer.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This trial tests a drug that helps your immune system target and kill myeloma cells after a stem cell transplant. It is for people with newly diagnosed multiple myeloma who still have minimal residual disease (small amounts of cancer) after their first transplant.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This early-phase study tests how safe and effective several treatment approaches are for people with multiple myeloma who have already had other treatments. Depending on your myeloma features and prior care, a study drug combination may be offered to try to control the disease.
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.